Eli Lilly cuts insulin-related out of pocket expense for diabetes patients in the U.S

Eli Lilly caps the out of pocket expense for insulin at £27.50/month for U.S patients.
U.S drugmaker's co-pay scheme will not cover the patients enrolled in government insurance.
Trump administration to reduce the out of pocket cost for insulin to £27.50/month.

Eli Lilly & Company (NYSE:LLY) announced a cap of £27.50/month on the out of pocket expense for insulin on Tuesday. The company said that it wishes to help the U.S patients that are facing financial challenges ascribed to the ongoing COVID-19 pandemic.

Jun 10, 2026, 04:48 AM

Stock market

Dow gains as Nasdaq slides on chip selloff, SpaceX IPO concerns

No results found

Loading articles...

Failed to load articles. Please try again.

Eli Lilly cuts insulin-related out of pocket expense for diabetes patients in the U.S

UK equities hover at three-week lows as investors assess global risks

Asian tech stocks slide as AI rally loses momentum amid valuation worries

Rolls-Royce share price faces a crucial test: rally or retreat ahead?

Meta is building a new $20B business, Truist says

Dow gains as Nasdaq slides on chip selloff, SpaceX IPO concerns